Orders by weight:
- Mice expressing human ACE2 are susceptible to infection by SARS-CoV-2, the virus that causes COVID-19. The hACE2 AC70 mouse model expresses human ACE2 cDNA under the control of the CAG promoter.
- ACE2 is the receptor bound by SARS-CoV-2 and SARS-CoV spike proteins during viral entry into host cells; these spike proteins have much higher binding affinity to human ACE2 compared to mouse ACE2.
- Following intranasal infection with 106 TCID50 SARS-CoV-2, hACE2 AC70 mice lost significant bodyweight by 3 days post-infection (dpi) and 100% of mice died by 5 dpi, whereas wild type control littermates maintained bodyweight and no mice died. Personal communication, Kent Tseng, UTMB.
- According to published reports, hACE2 AC70 mice express human ACE2 in lungs, kidneys, liver, heart, skeletal muscle, spleen, lymph nodes, pancreas, gastrointestinal smooth muscle and ganglia, vascular endothelium, adrenal and central nervous system tissues. Taconic has confirmed hACE2 mRNA expression in hemizygous male and female mice in the following tissues: lung, brain, stomach, small intestine, cecum, colon, kidney, heart and muscle. For most tissues, mRNA expression of human ACE2 is significantly higher than that of mouse Ace2.
- Due to the susceptibility of this mouse to SARS-CoV-2 and the current prevalence of this virus in the human population, special biosecurity precautions are required for housing and husbandry for hACE2 mice — both naïve mice and mice used in infection studies. A signed Acknowledgement of Biosecurity Precautions for Models Susceptible to SARS-CoV-2 is required prior to order.
- The hACE2 AC70 line is also susceptible to SARS-CoV, the virus which causes SARS. Following intra-nasal infection with SARS-CoV, hACE2 AC70 mice rapidly lose weight and die within days. SARS-CoV virus replicates primarily in lung and brain, and hACE2 AC70 mice develop moderate interstitial pneumonia. A signed Acknowledgement of Biosecurity Precautions for Models Susceptible to SARS-CoV-2 is required prior to order.
- The AC70 transgene is located on the X chromosome.
- Learn more about hACE2 mice for COVID-19 research.
- Non-profit researchers may obtain breeding rights by executing a limited breeding license. This license carries a nominal fee.
Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
Available now in study quantities.
Genetic Background: C57BL/6 is the predominant background strain, with contributions from C3H. The strain background is being moved onto C57BL/6NTac via backcrossing.
Origin: The hACE2 AC70 Mouse was generated by Kent Tseng et al. at the University of Texas Medical Branch at Galveston via pronuclear microinjection of a transgene into C57BL/6J x C3H/HeJ F1 zygotes. The transgene consists of human ACE2 cDNA under the control of the CAG promoter, consisting of the cytomegalovirus immediate-early enhancer and the chicken beta-actin promoter with the rabbit globin splicing and polyadenylation site. Multiple founder lines were established, including the AC70 line, which was subsequently backcrossed to C57BL/6. Taconic received the line in 2020, and the line was expanded via IVF rapid expansion using C57BL/6NTac females and hemizygous males. Taconic maintains breeding using C57BL/6NTac females by hemizygous males and/or hemizygous females by C57BL/6NTac males.
Color: Black and Black Agouti
- Tseng, C.-T. K.; Huang, C.; Newman, P.; Wang, N.; Narayanan, K.; Watts, D. M.; Makino, S.; Packard, M. M.; Zaki, S. R.; Chan, T.-S.; Peters, C. J. Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic for the Human Angiotensin-Converting Enzyme 2 Virus Receptor. Journal of Virology 2007, 81 (3), 1162–1173.
- Yoshikawa, N.; Yoshikawa, T.; Hill, T.; Huang, C.; Watts, D. M.; Makino, S.; Milligan, G.; Chan, T.; Peters, C. J.; Tseng, C.-T. K. Differential Virological and Immunological Outcome of Severe Acute Respiratory Syndrome Coronavirus Infection in Susceptible and Resistant Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. Journal of Virology 2009, 83 (11), 5451–5465.